Grimes & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361K	Hold	37,952	–	–	0.01%	338
2025 Q4	$296K	Sell	37,952 -16,011	-30%	-$116K	0.01%	385
2025 Q3	$410K	Buy	53,963 +489	+0.9%	+$4.07K	0.01%	331
2025 Q2	$479K	Sell	53,474 -19,233	-26%	-$179K	0.01%	272
2025 Q1	$545K	Sell	72,707 -2,568	-3%	-$20.7K	0.02%	232
2024 Q4	$566K	Hold	75,275	–	–	0.02%	239
2024 Q3	$572K	Hold	75,275	–	–	0.02%	223
2024 Q2	$465K	Buy	75,275 +3,836	+5%	+$21.2K	0.01%	227
2024 Q1	$363K	Sell	71,439 -916	-1%	-$5.15K	0.01%	251
2023 Q4	$433K	Sell	72,355 -1,220	-2%	-$7.07K	0.01%	232
2023 Q3	$521K	Buy	73,575 +903	+1%	+$6.49K	0.02%	204
2023 Q2	$512K	Buy	72,672 +350	+0.5%	+$2.81K	0.02%	205
2023 Q1	$603K	Buy	72,322 +415	+0.6%	+$4K	0.02%	184
2022 Q4	$825K	Sell	71,907 -40	-0.1%	-$499	0.03%	171
2022 Q3	$907K	Buy	71,947 +948	+1%	+$12.2K	0.05%	149
2022 Q2	$751K	Buy	70,999 +2,238	+3%	+$23.1K	0.04%	162
2022 Q1	$1.12M	Buy	68,761 +3,289	+5%	+$52.8K	0.06%	151
2021 Q4	$907K	Buy	65,472 +12,801	+24%	+$169K	0.04%	169
2021 Q3	$757K	Buy	52,671 +2,066	+4%	+$32.6K	0.03%	176
2021 Q2	$800K	Sell	50,605 -1,157	-2%	-$15.7K	0.03%	169
2021 Q1	$526K	Buy	51,762 +15,812	+44%	+$163K	0.03%	187
2020 Q4	$268K	Buy	35,950 +20,950	+140%	+$108K	0.01%	229
2020 Q3	$52K	Buy	+15,000	New	+$64.3K	﹤0.01%	246